-
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
Monday, September 23, 2024 - 2:01pm | 385Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk‘s (NYSE:NVO) mid...
-
Zynerba Pharmaceuticals R&D Expenses Reach $5.1M For Q1 2022, Here Are The Details
Monday, May 16, 2022 - 9:24am | 513Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), reported financial results for the first quarter ended March 31, 2022, revealing net loss of $8.5 million. Research and development expenses were $5.1 million for the first quarter of 2022, including stock-based compensation of $0.5 million. General and...
-
Zynerba's Shares Jump on CBD Zygel Trial Plans, Company Reports Cash Until 2024
Wednesday, May 12, 2021 - 2:12pm | 520Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a loss of 53 cents per share. First Quarter Highlights Cannabinoid-focused pharmaceutical company...